Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 20.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
18.00 23.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.11 5.04 9.16 2.2 69
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 20.50 GBX

Summit Therapeutics (SUMM) Latest News

More Summit Therapeutics News
Summit Therapeutics Takeover Rumours

Summit Therapeutics (SUMM) Discussions and Chat

Summit Therapeutics (SUMM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Summit Therapeutics trades in real-time

Summit Therapeutics (SUMM) Top Chat Posts

DateSubject
22/9/2020
09:20
Summit Therapeutics Daily Update: Summit Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Therapeutics was 20.50p.
Summit Therapeutics Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 30p while the 1 year low share price is currently 19p.
There are currently 335,873,208 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Summit Therapeutics Plc is £68,854,007.64.
05/3/2020
15:16
sikhthetech: 1gw, You mean this Barda funding of $1m? The clinical results expected 2nd half of 2021, which is after they expect to run out of money, as stated in their placing rns, isn't it?. "Eurofarma is an ideal partner for us with the necessary expertise to successfully market ridinilazole in Latin America, should it receive approval. We're pleased with the progress we have made in enrolling our Phase 3 clinical trials, and we look forward to the results of the trials expected in the second half of 2021." https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Therapeutics-To-Rec/81688333 From SMMT's rns: The placing provides funding until Jan 2021, so less than a year. "The Company's existing cash and funding arrangements will be sufficient to fund the Company's operating expenses, including the ongoing Phase 3 clinical trial of ridinilazole for the treatment of C. difficile infection, and capital expenditure requirements through to 31 January 2020. If approved and completed, the Company expects that the Fundraising will extend this runway by approximately 12 months to 31 January 2021. "
27/2/2020
20:34
sikhthetech: 1gw, "if they can come up with a new form of antibiotic that gains widespread acceptance then there is potentially a lot of money to be made." Why do you think Mr Duggan and Mr Zanganeh have around 75% holding between them, PLUS the warrants at 10% above placing price of 21p If they are successful they will it over at around the placing price of 21p... They only have enough money for less than a year.. If it's not successful then diluted placing or bust.. Takeover waiver no longer applies from 24th Feb " The Takeover Panel has confirmed that the Company will remain subject to the Code until such time as both (1) the proposed Board Restructuring has occurred, resulting in the Company's place of central management and control no longer being in the United Kingdom, Channel Islands and Isle of Man and (2) the Company's shares are no longer admitted to trading on AIM. Subject inter alia to the Cancellation Resolution being approved, it is expected that the Company will no longer be subject to the Code from 24 February 2020. " " For so long as both the Company's place of central management and control is outside the United Kingdom, Channel Islands and Isle of Man and the Company's shares are not traded on a regulated market or multilateral trading facility in the UK, the Code will not apply to the Company. Therefore in those circumstances Shareholders would not receive the protections afforded by the Code in the event there is a subsequent offer to acquire their shares in the Company." https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Announces-A-Propose/81299524
27/2/2020
20:23
1gw: STT - placings/dilutions are par for the course in biotech, especially early-stage biotechs with no revenues to speak of. What you hope as an investor is that the clinical progress they make means the share price goes up between placings. It's a high risk game, but if they can come up with a new form of antibiotic that gains widespread acceptance then there is potentially a lot of money to be made.
27/2/2020
19:49
sikhthetech: From the article... "Duggan has spent $75 million building up a 65% stake in Summit Therapeutics and his investment partner, Maky Zanganeh, the former chief operating officer of Pharmacyclics, has also purchased about 10% of the company." 75% plus warrants at 10% above the placing price. "But the last time Duggan bet on an antibiotics company, it collapsed into bankruptcy." From SMMT's rns: The placing provides funding until Jan 2021, so less than a year. "The Company's existing cash and funding arrangements will be sufficient to fund the Company's operating expenses, including the ongoing Phase 3 clinical trial of ridinilazole for the treatment of C. difficile infection, and capital expenditure requirements through to 31 January 2020. If approved and completed, the Company expects that the Fundraising will extend this runway by approximately 12 months to 31 January 2021. " Substantial holdings - Placing and warrants at 10% above placing price. "Robert W. Duggan is a substantial Shareholder and Glyn Edwards is a director of the Company. Both Mr Duggan and Mr Edwards are therefore related parties pursuant to the AIM Rules. Mr Duggan's participation in the Subscription and Mr Edwards' participation in the Placing, by way of subscription for 452,475 Placing Shares and receipt of 67,870 Investor Warrants, are deemed to be related party transactions (the "Related Party Transactions"). " https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Announces-A-Propose/81299524
24/2/2020
11:29
sikhthetech: The placing provides funding until Jan 2021, so less than a year. "The Company's existing cash and funding arrangements will be sufficient to fund the Company's operating expenses, including the ongoing Phase 3 clinical trial of ridinilazole for the treatment of C. difficile infection, and capital expenditure requirements through to 31 January 2020. If approved and completed, the Company expects that the Fundraising will extend this runway by approximately 12 months to 31 January 2021. " Substantial holdings - Placing and warrants at 10% above placing price. "Robert W. Duggan is a substantial Shareholder and Glyn Edwards is a director of the Company. Both Mr Duggan and Mr Edwards are therefore related parties pursuant to the AIM Rules. Mr Duggan's participation in the Subscription and Mr Edwards' participation in the Placing, by way of subscription for 452,475 Placing Shares and receipt of 67,870 Investor Warrants, are deemed to be related party transactions (the "Related Party Transactions"). " Takeover waiver no longer applies from 24th Feb " The Takeover Panel has confirmed that the Company will remain subject to the Code until such time as both (1) the proposed Board Restructuring has occurred, resulting in the Company's place of central management and control no longer being in the United Kingdom, Channel Islands and Isle of Man and (2) the Company's shares are no longer admitted to trading on AIM. Subject inter alia to the Cancellation Resolution being approved, it is expected that the Company will no longer be subject to the Code from 24 February 2020. " " For so long as both the Company's place of central management and control is outside the United Kingdom, Channel Islands and Isle of Man and the Company's shares are not traded on a regulated market or multilateral trading facility in the UK, the Code will not apply to the Company. Therefore in those circumstances Shareholders would not receive the protections afforded by the Code in the event there is a subsequent offer to acquire their shares in the Company." https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Announces-A-Propose/81299524
23/2/2020
17:49
sikhthetech: 1gw, what do you think of the funding. They say, they've only have enough to last until Jan 2021, so 11 months. So could be more placing/dilution over the next few months.. What do you think of the warrants with an exercisable price of 10% above the placing price of 21p? The placing provides funding until Jan 2021, so less than a year. "The Company's existing cash and funding arrangements will be sufficient to fund the Company's operating expenses, including the ongoing Phase 3 clinical trial of ridinilazole for the treatment of C. difficile infection, and capital expenditure requirements through to 31 January 2020. If approved and completed, the Company expects that the Fundraising will extend this runway by approximately 12 months to 31 January 2021. " Substantial holdings - Placing and warrants at 10% above placing price. "Robert W. Duggan is a substantial Shareholder and Glyn Edwards is a director of the Company. Both Mr Duggan and Mr Edwards are therefore related parties pursuant to the AIM Rules. Mr Duggan's participation in the Subscription and Mr Edwards' participation in the Placing, by way of subscription for 452,475 Placing Shares and receipt of 67,870 Investor Warrants, are deemed to be related party transactions (the "Related Party Transactions"). " Takeover waiver no longer applies from 24th Feb " The Takeover Panel has confirmed that the Company will remain subject to the Code until such time as both (1) the proposed Board Restructuring has occurred, resulting in the Company's place of central management and control no longer being in the United Kingdom, Channel Islands and Isle of Man and (2) the Company's shares are no longer admitted to trading on AIM. Subject inter alia to the Cancellation Resolution being approved, it is expected that the Company will no longer be subject to the Code from 24 February 2020. " " For so long as both the Company's place of central management and control is outside the United Kingdom, Channel Islands and Isle of Man and the Company's shares are not traded on a regulated market or multilateral trading facility in the UK, the Code will not apply to the Company. Therefore in those circumstances Shareholders would not receive the protections afforded by the Code in the event there is a subsequent offer to acquire their shares in the Company." https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Announces-A-Propose/81299524
23/2/2020
12:51
sikhthetech: Kirk, "200*1.46=292,000 converted £225395 value against a U.K. close value of £200k at 20p ish" ADR's approx 10% higher... Exchange rate would make a major difference.. If the £ jumps to the level it was just before the referendum, £1=$1.50 then the value of US would be lower... Using 20k blocks..using £1=$1.30 2K * 1.46 = $2,920 = £2,246 10K * 20.5p = £2,050 Using £1=$1.50, which is were exchange rate was pre-referendum... 2K * 1.46 = $2,920 = £1,946 So once Brexit negotiations, due to finish at end of year are favourable, no reason why the £ won't continue to gain ground and be back at around £1=$1.50 before the current placing money is due to finish.. Yet in the future the warrants will allow the placees to increase their holding at 10% above the placing price of 21p... Read the rns: Substantial holdings - Placing and warrants at 10% above placing price. "Robert W. Duggan is a substantial Shareholder and Glyn Edwards is a director of the Company. Both Mr Duggan and Mr Edwards are therefore related parties pursuant to the AIM Rules. Mr Duggan's participation in the Subscription and Mr Edwards' participation in the Placing, by way of subscription for 452,475 Placing Shares and receipt of 67,870 Investor Warrants, are deemed to be related party transactions (the "Related Party Transactions"). " The placing provides funding for less than a year. "The Company's existing cash and funding arrangements will be sufficient to fund the Company's operating expenses, including the ongoing Phase 3 clinical trial of ridinilazole for the treatment of C. difficile infection, and capital expenditure requirements through to 31 January 2020. If approved and completed, the Company expects that the Fundraising will extend this runway by approximately 12 months to 31 January 2021. " https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Announces-A-Propose/81299524
21/2/2020
13:26
sikhthetech: 1gw, what do you think of the funding. They say, they've only have enough to last until Jan 2021, so 11 months. So could be more placing/dilution over the next few months.. What do you think of the warrants with an exercisable price of 10% above the placing price of 21p? The placing provides funding for 10months. "The Company's existing cash and funding arrangements will be sufficient to fund the Company's operating expenses, including the ongoing Phase 3 clinical trial of ridinilazole for the treatment of C. difficile infection, and capital expenditure requirements through to 31 January 2020. If approved and completed, the Company expects that the Fundraising will extend this runway by approximately 12 months to 31 January 2021. " Substantial holdings - Placing and warrants at 10% above placing price. "Robert W. Duggan is a substantial Shareholder and Glyn Edwards is a director of the Company. Both Mr Duggan and Mr Edwards are therefore related parties pursuant to the AIM Rules. Mr Duggan's participation in the Subscription and Mr Edwards' participation in the Placing, by way of subscription for 452,475 Placing Shares and receipt of 67,870 Investor Warrants, are deemed to be related party transactions (the "Related Party Transactions"). " Takeover waiver no longer applies from 24th Feb " The Takeover Panel has confirmed that the Company will remain subject to the Code until such time as both (1) the proposed Board Restructuring has occurred, resulting in the Company's place of central management and control no longer being in the United Kingdom, Channel Islands and Isle of Man and (2) the Company's shares are no longer admitted to trading on AIM. Subject inter alia to the Cancellation Resolution being approved, it is expected that the Company will no longer be subject to the Code from 24 February 2020. " " For so long as both the Company's place of central management and control is outside the United Kingdom, Channel Islands and Isle of Man and the Company's shares are not traded on a regulated market or multilateral trading facility in the UK, the Code will not apply to the Company. Therefore in those circumstances Shareholders would not receive the protections afforded by the Code in the event there is a subsequent offer to acquire their shares in the Company." https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Announces-A-Propose/81299524
18/2/2020
20:12
sikhthetech: Read the rns: Takeover code waiver "The Fundraising is not being underwritten and is conditional (amongst other things) upon the passing by the Company's shareholders ("Shareholders") of a resolution to approve a waiver (the "Rule 9 Waiver"), which has been granted by the Takeover Panel, of certain obligations that would otherwise arise on Mr Duggan in connection with the Subscription pursuant to rule 9 of the City Code on Takeovers and Mergers (the "City Code"). " Substantial holdings - Placing and warrants at 10% above placing price. "Robert W. Duggan is a substantial Shareholder and Glyn Edwards is a director of the Company. Both Mr Duggan and Mr Edwards are therefore related parties pursuant to the AIM Rules. Mr Duggan's participation in the Subscription and Mr Edwards' participation in the Placing, by way of subscription for 452,475 Placing Shares and receipt of 67,870 Investor Warrants, are deemed to be related party transactions (the "Related Party Transactions"). " Takeover waiver no longer applies from 24th Feb " The Takeover Panel has confirmed that the Company will remain subject to the Code until such time as both (1) the proposed Board Restructuring has occurred, resulting in the Company's place of central management and control no longer being in the United Kingdom, Channel Islands and Isle of Man and (2) the Company's shares are no longer admitted to trading on AIM. Subject inter alia to the Cancellation Resolution being approved, it is expected that the Company will no longer be subject to the Code from 24 February 2020. " " For so long as both the Company's place of central management and control is outside the United Kingdom, Channel Islands and Isle of Man and the Company's shares are not traded on a regulated market or multilateral trading facility in the UK, the Code will not apply to the Company. Therefore in those circumstances Shareholders would not receive the protections afforded by the Code in the event there is a subsequent offer to acquire their shares in the Company." The placing provides funding for LESS THAN A YEAR. "The Company's existing cash and funding arrangements will be sufficient to fund the Company's operating expenses, including the ongoing Phase 3 clinical trial of ridinilazole for the treatment of C. difficile infection, and capital expenditure requirements through to 31 January 2020. If approved and completed, the Company expects that the Fundraising will extend this runway by approximately 12 months to 31 January 2021. " https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Announces-A-Propose/81299524 I think Mr Duggan will take over the company at around the current price within the next 12 months.
06/2/2020
13:12
sikhthetech: 1gw "they would tap the US equity markets for more funds through a placing" They already have warrants from the recent placing, why would they then tap the US equity market? I don't think it's a coincidence that Mr Duggan's holding's is near 75% mark. "In addition, a total of 26,306,765 warrants ("Investor Warrants") are proposed to be granted to the participants in the Subscription and the Placing, providing for the right to subscribe for an aggregate of 26,306,765 ordinary shares at a premium of 10 per cent. to the Offer Price. " "If approved and completed, the Company expects that the Fundraising will extend this runway by approximately 12 months to 31 January 2021. " https://uk.advfn.com/stock-market/london/summit-therapeutics-SUMM/share-news/Summit-Therapeutics-plc-Summit-Announces-A-Propose/81299524
Summit Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SUMM
Summit The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200922 08:23:44